– Received FDA Orphan Drug and Fast Track designations for novel glioblastoma radiotherapy –

Link:
Plus Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

SANTA CLARA, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease will webcast an investor update at the virtual VIVA20 on Saturday, November 7 at 11:00 a.m. eastern time. Dr. William Gray, M.D., FACC, FSCAI, Chief of the Division of Cardiovascular Disease at Main Line Health, Wynnewood, PA; Co-Principal Investigator of DISRUPT PAD III will present the results of the PAD III study and then will be joined by Dr. Sarang Mangalmurti, M.D., Interventional Cardiologist and Endovascular Specialist, Bryn Mawr Hospital – Main Line, Doug Godshall, Chief Executive Officer of Shockwave and Keith Dawkins, Chief Medical Officer of Shockwave to discuss the results and answer questions from investors about the study.

Link:
Shockwave Medical Announces VIVA20 Investor Update and Conference Call Discussing Third Quarter 2020 Results

STOUGHTON, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.

Go here to see the original:
Collegium to Host Conference Call to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update

BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the third quarter ended September 30, 2020, and provide an update on recent business highlights, on November 5, 2020.

Read more from the original source:
X4 Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020

MONTREAL, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that management will be presenting at the following upcoming virtual investor conferences.

See more here:
Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020

GUILFORD, Conn., Oct. 22, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that John D. Vandermosten, CFA, Biotechnology Analyst of Zacks Small Cap Research division at Zacks Investment Research and his team (“Zacks”) has initiated analyst coverage on Bioasis Technologies Inc.

Continue reading here:
Bioasis Announces Analyst Coverage Initiated by Zacks Investment Research

REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2020 financial results will be released after market close on Thursday, November 5, 2020. Starting at 4:30 p.m. EST, Coherus’ management team will host a conference call to discuss financial results and provide a general business update.

More:
Coherus BioSciences to Report Third Quarter Financial Results on November 5th

RESEARCH TRIANGLE PARK, N.C., Oct. 22, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2020 financial results on Thursday, November 5, 2020.

Follow this link:
BioCryst to Report Third Quarter 2020 Financial Results on November 5

PRINCETON, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- KBP Biosciences Holdings Limited (KBP Biosciences), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative therapeutics for the treatment of major diseases with large underserved patient populations, today announced upcoming data to be presented at the American Society of Nephrology (ASN) Annual Meeting, being held in a virtual format from October 22-25, 2020. Frederic Jaisser, Head of the Physiology Department, Cordeliers Research Center, Research Director, INSERM, is presenting an abstract entitled: “The non-steroidal mineralocorticoid receptor antagonist KBP-5074 limits albuminuria with improved efficacy and safety compared to eplerenone.”

Continued here:
KBP Biosciences Announces Data Presentation at the American Society of Nephrology Annual Meeting

California cannabis industry leader adds veteran executive and strategic advisor to leadership team California cannabis industry leader adds veteran executive and strategic advisor to leadership team

See the original post:
Indus Holdings, Inc. Welcomes Bruce Gates to Board of Directors; Announces Results of Annual Shareholder Meeting

Milestone payment further bolsters Innate’s cash position

View original post here:
First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third quarter 2020 financial results and corporate update conference call and live audio webcast on Thursday, October 29th at 8:30 a.m. EDT.

Read the original:
Genocea to Host Third Quarter 2020 Corporate Update Conference Call & Webcast

Read the original post:
Nicox Selects Development Candidate in a New Class of NO-mediated Intraocular Pressure (IOP) Lowering Agents

REGULATED INFORMATION

More here:
Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofipôle SA

REGULATED INFORMATION

See the original post:
Bone Therapeutics SA: Information on the total number of voting rights and shares

•      The increased liquidity will be used to prepare for the launch of daridorexant and further fund Idorsia’s diversified pipeline

Original post:
Idorsia successfully completes capital increase with gross proceeds of CHF 535.5 million

NEWS RELEASE - REGULATED INFORMATION 21 OCTOBER 2020, 07:00 A.M. CEST

The rest is here:
MDxHealth Provides Q3-2020 Business Update

GUANGZHOU, China, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that new data for its early detection ELSA-seq test will be presented at the upcoming European Society for Medical Oncology (ESMO) Asia Virtual Congress, on Friday, November 20.

More:
Burning Rock to Present Data on Its Early Detection ELSA-seq at ESMO Asia Virtual Congress 2020

ORION CORPORATION            INTERIM REPORT 1-9/2020    21 OCTOBER 2020 at 12:00 noon EEST

See original here:
Orion Group Interim Report 1-9/2020

Oslo (Norway), 21 October 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today informed that AstraZeneca has elected not to enter into a definitive agreement for the fimaNAc technology.

Continue reading here:
PCI Biotech: Preclinical research collaboration with big pharma ended